A phase II randomized, double-blind, placebo-controlled, dose-ranging study of belimumab of patients with active systemic lupus erythematosus. Arthritis Rheum. 61 , 1168–1178 (2009).

Lupus activity was defined by presence of SS ... There were initially three belimumab groups (1, 4 or 10 mg/kg every 4 weeks) and a placebo group enrolled in a 52-week trial.

In a new study published in Lupus Science & Medicine, researchers explored the efficacy of using a combination of belimumab and standard immunotherapy compared to standard immunotherapy alone in ...

B cells have important pathogenic roles in systemic lupus erythematosus (SLE): they ... now report favorable results for their phase I trial of belimumab—a fully human, neutralizing, monoclonal ...

The US FDA has approved GSK’s Benlysta (belimumab) intravenous infusion for the treatment of children with lupus. While childhood-onset lupus is rare, when diagnosed, it is generally more active ...

GlaxoSmithKline’s Benlysta has been on the market for almost a decade, but it still has some tricks up its sleeve – it’s just become the first and only FDA-approved treatment for lupus ...

decades of hard work led to three new drugs receiving FDA-approval for the treatment of lupus and lupus nephritis: Belimumab (Benlysta), Voclosporin (Lupkynis), and Aanifrolumab (Saphnelo). The Lupus ...

GLP-1 RAs might lower kidney failure risk in patients with lupus nephritis by reducing pro ... Nearly 1 in 7 patients were treated with belimumab or voclosporin. Fewer than 1 in 10 were taking ...

I think the data are suitably strong to justify the approval of belimumab as a treatment for ... 2010 Future Medicine Ltd. BILAG: The British Isles Lupus Assessment Group; ITT: Intent-to-treat ...